Composition comprising at least one triterpene and / or at least one triterpenoid and / or at least

专利摘要:
The present invention relates to a composition in the form of a thermoformed extrudate comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least one polymer chosen from the group consisting of natural proteins or synthetic, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least one first amorphous phase and optionally a second crystalline phase. The present invention also relates to the process for manufacturing such a composition by thermoforming and to its use.
公开号:BE1027350B1
申请号:E20205463
申请日:2020-06-24
公开日:2021-06-22
发明作者:Jean-Noël Tilman；Daniela Martinez-Tovar；Fabian Priem；Céline Meinguet；Yvan Dierckxsens；Benoît Wery；Cristina Loira-Pastoriza
申请人:Eleonor；Tilman；
IPC主号:

专利说明:

Composition comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms The present invention relates to a composition comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms, to its manufacturing process and to its use.
Triterpenes and triterpenoids are widely distributed in the plant kingdom and exhibit varied biological activities. The terms “triterpenes” and “triterpenoids” denote substances of organic origin at C30 (30 carbon atoms) of the terpene family. Generally, the term "triterpene" is used to describe natural triterpenes and the broader term "triterpenoid" refers to both natural triterpenes and their functionalized and / or metabolized derivatives which maintain the triterpene structure. The classification into either of the categories of triterpenes and triterpenoids is not always clear in the literature and varies among authors. This is why the terms "triterpenes" and "triterpenoids" are frequently used to describe and refer to the same C30 terpene compounds (Parmar et al., Neuropharmacological effects of triterpenoids. Phytopharmacology 2013, 4 (2), 354-372). For example, some classifications consider boswellic acids to be pentacyclic triterpenoids while other classifications consider these same molecules to be pentacyclic triterpenes.
Two main categories can be distinguished: tetracyclic triterpenes or triterpenoids and pentacyclic triterpenes or triterpenoids. Among the tetracyclic triterpenes or triterpenoids, we find in particular oleandrine, euphol and cucurbitacins. In the category of triterpenes or pentacyclic triterpenoids, we find in particular betulinic acid, oleanolic acid, boswellic acids, ursolic acid, lupeol, Asian acid and maslinic acid.
Among the triterpenes or pentacyclic triterpenoids, the following groups of compounds are distinguished: hopane, arboran, fernan, gammaceran, onoceran, serratane, stictane, oleanane, ursane, taraxastane and lupane.
The tetracyclic triterpenes or triterpenoids and the pentacyclic triterpenes or triterpenoids constitute the most interesting groups of natural products because of their various pharmacological activities: anticancer, anti-inflammatory, analgesic, antimicrobial (antibacterial, antiviral, antifungal, antiplasmodic, etc.), hepatoprotective (antihypertensive, antidiabetic, antinyperlipidemic, antioxidant, ...), neuroprotective (antidepressant, antifatigue, actions against neurological disorders such as Parkinson's, Alzheimer's, ...).
In particular and without limitation, boswellic acids are potent anti-inflammatories, inhibitors of the production of inflammation mediators, inhibitors of the activation of NF-kappaB, decrease interleukins IL-1, IL- 2, IL-4, IL-6 and interferon-gamma; act on antibody production and cell-mediated immunity; inhibit 5-lipoxygenase (5-LOX) involved in the biosynthesis of leukotrienes by acting directly on an enzymatic site through the triterpene or pentacyclic triterpenoid structure and induce apoptosis in certain cancer cells by inhibiting topoisomerase. The anti-inflammatory properties of boswellic acids are used in particular for the treatment of several diseases where inflammation is involved, such as osteoarthritis, arthritis, rheumatoid arthritis, asthma, psoriasis or chronic inflammatory diseases of the intestine.
Note that there are many a- and B-boswellic acids such as a-boswellic acid, acetyl-a-boswellic acid,
B-boswellic acid, acetyl-B-boswellic acid, 9,11-dehydro-a-boswellic acid, acetyl-9,11-dehydro-a-boswellic acid, 9,11 acid - dehydro-B-boswellic, acetyl-9,11-dehydro-B-boswellic acid, 11-keto-B-boswellic acid, 11-keto-a-boswellic acid, 3-acetyl acid -11- keto-a-boswellic or 3-acetyl-11-keto-B-boswellic acid.
It is widely recognized that triterpenes, triterpenoids and their glycosylated forms, in particular as tetracyclic triterpenes or triterpenoids and that triterpenes or pentacyclic triterpenoids, are compounds which are very little or even completely insoluble in the water in which they do not disperse. moreover only slightly or not at all, these compounds therefore exhibiting very low bioavailability. However, despite their low bioavailability / bioaccessibility (that is to say despite the small fraction of the administered dose which actually reaches the bloodstream in unchanged form) but also despite their low solubility and / or despite their low dispersion, in particular in the intestinal environment, the positive effects of triterpenes and triterpenoids and their glycosylated forms, in particular of tetracyclic triterpenes or triterpenoids and of pentacyclic triterpenes or triterpenoids, on various pathologies make them molecules of interest for administration to the human being and / or for veterinary use.
This is why numerous methodologies and numerous processes have been developed in order to formulate these compounds in the form of spherical particles, flakes, pellets or even granules. In particular, extrusion techniques can be used such as, for example, the extrusion-spheronization technique or the extrusion granulation technique (TSG or Tween Screw Granulation).
The extrusion-spheronization technique, as described for example in document EP1391426, makes it possible to produce round particles of homogeneous size from a wet mass (containing an active substance and at least one excipient) which has passed through a grid having a predetermined mesh size before drying the particles thus obtained. More particularly, this powder shaping process is based on the following steps: mixing an active substance and at least one excipient, wet granulation (compaction) of the mixture obtained previously, extrusion of the compacted mixture to obtain an extrudate, spheronizing the extrudate to form spherical particles / granules and drying the resulting spherical particles / granules.
The technique of granulation by extrusion, as described for example in document US Pat. No. 5,260,074, for its part makes it possible to obtain intermediate products for the preparation of tablets and capsules. This technique is based on a granulation (compaction) of substances in the form of powders in an extruder to give rise to the formation of granules at the outlet thereof.
Unfortunately, it appears that the current formulations comprising triterpenes and / or triterpenoids and / or their glycosylated forms, in particular tetracyclic triterpenes or triterpenoids and / or pentacyclic triterpenes or triterpenoids, are not very suitable because of their too low or even of their non-solubility and / or because of their too low or even their non-dispersion in the aqueous phase and / or because of the low release of these compounds from these formulations, which ultimately results in a low bioavailability / bioaccessibility of these molecules of interest. Note that it also appears that the current manufacturing processes for these formulations are restrictive and difficult to implement.
By the terms “dispersion in aqueous phase (in aqueous medium)”, it is understood, within the meaning of the present invention, a system composed of two phases in which one of the two phases, called the dispersed phase, is finely divided in the 'other, called the dispersant phase. This dispersion can be molecular (solution), colloidal (dispersion of submicron particles) or coarser (dispersion of particles greater than one µm). More particularly, according to the invention, the terms “dispersion in aqueous phase” denote the suspensions,
consist of a solid phase dispersed in an aqueous phase (liquid).
For the purposes of the present invention, the term "solubility" refers to the ability of a substance, called a solute, to dissolve in another substance, called a solvent, to form a homogeneous mixture called a solution.
The object of the invention is to alleviate at least in part the drawbacks of the state of the art by providing (1) a composition comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms. whose solubility (s) and / or dispersion (s) in aqueous phase (aqueous medium) is (are) increased such that the bioavailability (s) of these compounds either (are) significantly increased and (2) a method of manufacturing such a composition which is easy to process, which is flexible, which is economically profitable and which ensures that said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms is (are) present (s) and distributed homogeneously in the final composition obtained.
Furthermore, the invention intends to provide a composition which is stable over time, that is to say which retains its properties in terms of solubility and / or dispersion of said at least one triterpene and / or of said at least one. triterpenoid and / or said at least one of their glycosylated forms and which retains its properties in terms of the rate of release of these compounds over time from a composition (formulation) according to the invention, this in particular in phase aqueous and more particularly in the intestinal environment.
To at least partially resolve these problems, according to the invention, a composition is provided in the form of a thermoformed extrudate comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least a polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase, said composition comprising at least one plasticizer.
In particular, according to the invention, said at least one polymer is a thermoplastic polymer, that is to say a polymer having the property of softening when it is heated sufficiently, but which, on cooling, becomes hard again.
According to one embodiment, there is therefore provided according to the invention, a composition in the form of a thermoformed extrudate comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least one natural or synthetic protein as polymer, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase.
According to one embodiment, there is also provided according to the invention, a composition in the form of a thermoformed extrudate comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least one natural or synthetic oligosaccharide as polymer, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase.
According to one embodiment, there is also provided according to the invention, a composition in the form of a thermoformed extrudate comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least one natural or synthetic polysaccharide as polymer, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase.
By the term "extrudate", it is understood, within the meaning of the present invention, a material which leaves an extruder, in particular from the die of an extruder.
By the terms “thermoformed extrudate”, it is understood, within the meaning of the present invention, a material which leaves an apparatus, in particular which leaves an extruder, in which it has undergone a transformation by the effect of heat, possibly by the combined effect of heat and shear forces from a worm screw. Such a transformation by the effect of heat, possibly by the combined effect of heat and shear forces of an endless screw, can be obtained with the technique of hot extrusion (HME or Hot Melt Extrusion ).
In particular, a thermoformed extrudate according to the invention is an extrudate in which the active principle (s) (said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms) and / or said at least one polymer is / are melted.
In particular, the composition according to the invention, more particularly the composition in the form of a thermoformed extrudate according to the invention, is a solid dispersion in which said at least one triterpene and / or said at least one triterpenoid and / or said at least one triterpene. at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase is / are dispersed in said at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures.
According to one embodiment, there is therefore provided according to the invention, a composition in the form of a thermoformed extrudate comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least one natural protein. or synthetic as a polymer, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and _ optionally a second crystalline phase, said composition being a solid dispersion in which said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms is / are dispersed in said at least one natural or synthetic protein as a polymer, which is / was melted.
According to one embodiment, there is also provided according to the invention, a composition in the form of a thermoformed extrudate comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least one natural or synthetic oligosaccharide as polymer, said at least one triterpene andor said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase, said composition being a dispersion solid in which said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms is / are dispersed in said at least one natural or synthetic oligosaccharide as a polymer, which is / has been melted.
According to one embodiment, there is also provided according to the invention, a composition in the form of a thermoformed extrudate comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least one natural or synthetic polysaccharide as polymer, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase, said composition being a solid dispersion in which said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms is / are dispersed in said at least one natural or synthetic polysaccharide as polymer, which one is / has been melted.
A thermoformed extrudate according to the invention is obtained by hot thermoforming, in particular by hot thermoforming by the hot extrusion technique. According to the invention, hot thermoforming therefore relates more particularly to the technique of hot extrusion.
There is therefore provided according to the invention a composition obtained by hot thermoforming in the form of a thermoformed extrudate obtained by hot thermoforming, in particular obtained by hot extrusion, said composition comprising at least one triterpene and / or at least one triterpenoid. and / or at least one of their glycosylated forms and at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase.
A thermoformed extrudate according to the invention can therefore be obtained according to the hot extrusion technique which makes it possible to achieve the molecular dispersion of an active agent (active substance) within a polymer matrix (within a polymer) for form solid dispersions. This solid dispersion is possible thanks to a supply of heat and possibly thanks to the stress applied by the movement of the endless screws on the material in an extruder. Finally, the hot extrusion gives rise, at the outlet, to the formation of a thermoformed extrudate in the form of a rod which can then in particular be pelletized or crushed.
If the extrusion-spheronization technique and the extrusion granulation technique as described above are carried out without the addition of heat (heating) and they typically require a liquid phase (generally water) to obtain spherical particles and / or granules, the hot extrusion technique can be carried out without supplying this liquid phase but relies on supplying heat (heating) to ensure transformation of the material by thermoforming.
Moreover, if the extrusion-spheronization technique and the extrusion granulation technique consist of an agglomeration of powder granules while trying as much as possible to keep the initial properties of the constituents of these powders, the hot extrusion technique gives instead of a transformation of the material, in particular a glassy structure ("glassy structure") obtained under the action of heat (heating), the particles constituting the powders are no longer all present in their initial form ( native) crystalline at the end of the hot extrusion process but having undergone transformation by thermoforming.
By the terms “comprising at least a first amorphous phase and optionally a second crystalline phase”, it is understood, within the meaning of the present invention, that said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms can (can) either comprise 100% by mass of an amorphous phase, or it (s) can (can) simultaneously comprise a first amorphous phase and a second crystalline phase, the sum of the percentages by mass first and second phases being in this case equal to 100. In other words, the composition according to the invention can comprise said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their forms glycosylated (1) totally in amorphous form or (2) partly in amorphous (phase) form and partly in crystalline (phase) form.
Note that a phase is said to be amorphous when the atoms constituting it do not respect any order at medium and long distance, which distinguishes it from a so-called crystalline phase.
The composition according to the invention is therefore in the form of a thermoformed extrudate in which said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms (active principle) comprises (comprise) at least a first amorphous phase and optionally a second crystalline phase, which or which phase (s) is / are dispersed within at least one polymer chosen from the group consisting of natural or synthetic proteins, natural oligosaccharides or synthetic, natural or synthetic polysaccharides, their derivatives and their mixtures.
By the terms “natural protein”, it is understood within the meaning of the present invention any protein naturally present in the living world, in particular a plant or animal protein.
By the terms "synthetic protein", it is understood within the meaning of the present invention any protein which is the subject of human intervention, in particular a protein obtained at the start of a chemical or biochemical or biotechnological process.
By the terms “natural oligosaccharides” and “natural polysaccharides”, it is understood within the meaning of the present invention any oligosaccharide and any polysaccharide naturally present in the living world, in particular an oligosaccharide or a plant or animal polysaccharide.
By the terms “synthetic oligosaccharides” and “synthetic polysaccharides”, it is understood within the meaning of the present invention any oligosaccharide and any polysaccharide which is the subject of human intervention, in particular any oligosaccharide and any polysaccharide obtained from a chemical or biochemical or biotechnological process.
It has been determined, in the context of the present invention, that such a composition in the form of a thermoformed extrudate comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms as principle ( s) active agent (s) and at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures and in which said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprises (comprise) at least a first amorphous phase and optionally a second crystalline phase exhibits one (s) solubility (s) and / or one (s) distinctly higher dispersion (s) in aqueous phase (aqueous medium) of said at least one triterpene and / or of said at least one triterpenoid and / or of said at least one of their glycosylated forms.
Furthermore, it has been shown that such a composition according to the invention exhibits significantly increased bioavailability / bioaccessibility (s) of said at least one triterpene and / or of said at least one triterpenoid and / or or of said at least one of their glycosylated forms with respect to the bioavailability / bioaccessibilities observed for the current compositions.
According to the invention, the active principle (s), that is to say said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase, is (are) dispersed / distributed / distributed homogeneously within at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, the active principle (s) and / or said at least one polymer being melted during the manufacturing process by thermoforming implemented according to the invention and described later.
In addition, a composition according to the invention can be stored for several months without its properties being altered.
In particular, it has been demonstrated that a composition according to the invention retains its properties in terms of solubility (ies) and / or dispersion (s) in aqueous phase (aqueous medium) of said at least one triterpene and / or of said at least one triterpenoid and / or of said at least one of their glycosylated forms and in terms of the rate of release of this compound (s) over time from a composition / formulation according to the invention, this in particular in the aqueous phase.
Advantageously, according to the invention, said thermoformed extrudate comprises a thermoformed mixture of said at least one triterpene and / or of said at least one triterpenoid and / or of said at least one of their glycosylated forms and of said at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures.
Alternatively, according to the invention, said thermoformed extrudate consists of a thermoformed mixture of at least one triterpene and / or of at least one triterpenoid and / or of at least one of their glycosylated forms and of at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures.
There is therefore provided according to the invention a thermoformed extrudate obtained by hot thermoforming, in particular obtained by hot extrusion, said thermoformed extrudate comprising a thermoformed mixture of at least one triterpene and / or at least one triterpenoid and / or of at least one of their glycosylated forms and of at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures.
By the terms “thermoformed mixture”, it is understood, within the meaning of the present invention, a mixture which leaves an apparatus, in particular which leaves an extruder, in which it has undergone a transformation by the effect of heat, possibly by the combined effect of heat and shear forces from a worm screw. Such transformation by the effect of heat, possibly by the combined effect of heat and shear forces of an endless screw, can be achieved with the technique of hot extrusion (HME).
In particular, a thermoformed mixture according to the invention is a mixture in which the active principle (s) (said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms) and / or said at least one polymer is / are melted / was / were melted.
According to the invention, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprises (comprise) a first amorphous phase.
Advantageously, according to the invention, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms mainly comprises (comprise) at least one first amorphous phase.
Preferably, according to the invention, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprises between 51 and 100% by mass of an amorphous phase and between 0 and 49 % by mass of a crystalline phase.
By the terms “predominantly at least one first amorphous phase”, it is therefore understood, within the meaning of the present invention, that said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprises (comprise) between 50 and 100% by mass of an amorphous phase and between 0 and 50% of a crystalline phase, more particularly than said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprises (comprise) between 51 and 100% by mass of an amorphous phase and between 0 and 49% of a crystalline phase.
Advantageously, according to the invention, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms is tetracyclic, such as for example oleandrine, euphol or cucurbitacin, or pentacyclic , such as, for example, betulinic acid, oleanolic acid, a boswellic acid, ursolic acid, lupeol, asiatic acid, madecassic acid, maslinic acid, jujubogenin or pseudojujubogenine.
Glycosylated forms of triterpenes, such as, for example, ginsenosides, also fall within the scope of the present invention. Glycosylated forms of triterpenoids, such as, for example, bacosides, asiaticosides and a-hederin also fall within the scope of the present invention.
Advantageously, according to the invention, said boswellic acid is chosen from the group consisting of a- and B-boswellic acids, for example a-boswellic acid, acetyl-a-boswellic acid, B-boswellic acid, acetyl-B-boswellic acid, 9,11-dehydro-o-boswellic acid, acetyl-9,11-dehydro-a-boswellic acid, 9,11-dehydro-B-boswellic acid, acetyl-9,11-dehydro-B-boswellic acid, 11-keto-B-boswellic acid, 11-keto-a-boswellic acid, 3-acetyl-11-keto-a- boswellic, 3-acetyl-11-keto-B-boswellic acid.
Preferably, according to the invention, said natural or synthetic proteins are chosen from the group consisting of glycoproteins, collagens and / or collagen hydrolysates, plant proteins, animal proteins, their derivatives and their mixtures.
By the terms “collagen hydrolyzate”, it is understood, within the meaning of the present invention, gelatins and hydrolyzed collagens or collagen peptides. The terms “collagen hydrolyzate” therefore encompass gelatins having the capacity to gel, but also hydrolyzed collagens or collagen peptides which may or may not have the capacity to gel.
For example, when said at least one natural or synthetic protein is collagen or gelatin, it may be collagen or gelatin of animal origin (fish, pork, beef, etc.). For example, when said at least one natural or synthetic protein is a vegetable protein, it may be a protein from soy, pumpkin, rice, wheat, peas or nuts.
This list is not exhaustive.
Preferably, according to the invention, said collagens and / or said collagen hydrolysates have a molecular weight of between 50 and 300,000 Da, preferably between 100 and 275,000 Da, preferably between 150 and 250,000 Da, preferably between 200 and 225,000 Da. , preferably between 250 and 200,000 Da, preferably between 300 and 175,000 Da, preferably between 350 and 150,000 Da, preferably between 400 and 125,000 Da, preferably between 450 and 100,000 Da, preferably between 500 and 75,000 Da, of preferably between 550 and 50,000 Da, preferably between 600 and 40,000 Da, preferably between 650 and 30,000 Da, preferably between 700 and 20,000 Da, preferably between 750 and 10,000 Da, preferably between 800 and 9,000 Da, preferably between 850 and 8000 Da, preferably between 900 and 7000 Da, preferably between 950 and 6000 Da, preferably between 1000 and 5000 Da, preferably between 1050 and 4000 Da, preferably between 1100 and 3000 Da, preferably between 1150 and 2000 Da, preferably between 12 00 and 1000 Da.
Advantageously, according to the invention, said collagens and / or said collagen hydrolysates have a molecular weight of between 1000 and 300000 Da, preferably between 1500 and 150,000 Da, preferably between 2000 and 60,000 Da.
Preferably, according to the invention, said collagens and / or said collagen hydrolysates have a molecular weight equal to 50 Da or equal to 100 Da or equal to 150 Da or equal to 200 Da or equal to 250 Da or equal to 300 Da or equal to 350 Da or equal to 400 Da or equal to 450 Da or equal to 500 Da or equal to 550 Da or equal to 600 Da or equal to 650 Da or equal to 700 Da or equal to 750 Da or equal to 800 Da or equal to 850 Da or equal to 900 or equal to 950 Da or equal to 1000 Da or equal to 1100 Da or equal to 1200 or equal to 1300 Da or equal to 1400 Da or equal to 1500 Da or equal to 1600 Da or equal at 1700 Da or equal to 1800 Da or equal to 1900 Da or equal to 2000 Da or equal to 2500 Da or equal to 3000 Da or equal to 3500 Da or equal to 4000 Da or equal to 4500 Da or equal to 5000 Da or equal at 5500 Da or equal to 6000 Da or equal to 6500 Da or equal to 7000 Da or equal to 7500 Da or equal to 8000 Da or equal to 8500 Da or equal to 9000 Da or equal to 9500 Da or equal to 10,000 Da or equal at 12,500 Da or equal to 15,000 Da or equal to 17,500 Da or equal to 20,000 Da or equal to 22,500 Da or equal to 25,000 Da or equal to 27,500 Da or equal to 30,000 Da or equal to 32,500 Da or equal to 35,000 Da or equal to 37,500 Da or equal to 40,000 Da or equal to 42,500 Da or equal to 45,000 Da or equal to 47,500 Da or equal to 50,000 Da or equal to 55,000 Da or equal to 60,000 Da or equal to 65,000 Da or equal to 70,000 Da or equal to 75,000 Da or equal to 80,000 Da or equal to 85,000 Da or equal to 90,000 Da or equal to 100,000 Da or equal to 110,000 Da or equal to 120,000 Da or equal to 130,000 Da or equal to 140,000 Da or equal to 150,000 Da or equal to 160,000 Da or equal to 170,000 Da or equal to 180,000 Da or equal to 190,000 da or equal to 200,000 Da or equal to 210,000 Da or equal to 220,000 Da or equal to 230,000 Da or equal to 240,000 Da or equal to 250,000 Da or equal to 260,000 Da or equal to 270,000 Da or equal to 280,000 Da or equal to 290,000 Da or equal to 300,000 Da.
According to one embodiment according to the invention, when said at least one natural or synthetic protein is collagen, the latter has a molecular weight of between 900 and 7000 Da, preferably a molecular weight of between 950 and 5000 Da, preferably a molecular weight between 1000 and 3000 Da.
According to one embodiment according to the invention, when said at least one natural or synthetic protein is collagen, the latter has a molecular weight equal to 2000 Da or equal to 3000 Da or equal to 5000 Da or equal to 50,000 Da.
According to one embodiment according to the invention, when said at least one natural or synthetic protein is gelatin, the latter has a molecular weight of between 900 and 6000 Da, preferably a molecular weight of between 950 and 5000 Da, preferably a molecular weight between 1000 and 3000 Da. According to one embodiment according to the invention, when said at least one natural or synthetic protein is gelatin, the latter has a molecular weight equal to 2000 Da or equal to 3000 Da or equal to 5000 Da or equal to 50,000 Da.
According to one embodiment according to the invention, when said at least one natural or synthetic protein is a hydrolyzed collagen or a collagen peptide, the latter has a molecular weight of between 900 and 6000 Da, preferably a molecular weight of between 950 and 5000 Da, preferably a molecular weight of between 1000 and 3000 Da.
According to one embodiment according to the invention, when said at least one natural or synthetic protein is a hydrolyzed collagen or a collagen peptide, the latter has a molecular weight equal to 2000 Da or equal to 3000 Da or equal to 5000 Da or equal to 50,000 Da.
Preferably, according to the invention, said oligosaccharides are chosen from the group consisting of cyclodextrin, raffinose, rnamminose, rhamnose, stachyose, verbascose, trehalose, lactose, lactulose, maltose, their derivatives. and their mixtures.
Advantageously, according to the invention, said natural or synthetic polysaccharides are chosen from the group consisting of starches (corn starch, potato starch, pregelatinized starch, etc.), fibers (acacia, inulin, alginates, carrageenans, pectin, ...), celluloses and hemicelluloses (for example hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose phthalate, - hydroxypropymethylcellulose (HPMC), hydroxypropymethylcellulose acetosuccinate, cellulose acetobutyrate, cellulose acetate phthalate), glycogen, B-glucan, inulin, amylopectin, amylose, dextrin, maltodextrin, isomaltose, xylan, pullulan, agar-agar, carrageenans, mannans, fucoidan, gums (xanthan, guar, mastic or gum arabic, ...), chitosan, chitin, xanthan, levan, neoserine, hyaluronic acid, hyaluronates , chondroitin sulfate, dermatan sulfate, ker atan sulfate, their derivatives and their mixtures.
According to one embodiment, the composition according to the invention further comprises at least one additional natural or synthetic polymer chosen from the group consisting of polyvinyl acetate, polyvinylpyrrolidone (PVP), polyvinylpyrrolidone-co- acetate. vinyl, polyethylene-co-vinyl acetate, co-methacrylic acid polyvinyl acetate, polyethylene oxide, polylactide-co-glycolide, polyvinyl alcohol, polycarbophil, polycaprolactone, carnauba wax, ethylene-vinyl copolymer, lecithin, castor oil, hydrogenated soybean oil, waxes, isomalt, their derivatives and mixtures thereof.
The composition according to the invention further comprises at least one plasticizer.
The addition of a plasticizer in a composition according to the invention makes it possible to obtain a composition according to the invention through a manufacturing process where temperatures below the melting points of said at least one triterpene and / or of said at least one triterpenoid and / or said at least one of their glycosylated forms and the polymer can be used in order to guarantee all the same a melting of these two compounds and the dispersion / distribution / distribution of said at least one triterpene and / or of said at least one triterpenoid and / or said at least one of their glycosylated forms within the polymer.
Preferably, according to the invention, said plasticizer is chosen from the group consisting of polyols (glycerol, sorbitol, mannitol, etc.), lipids (fatty acids, fatty acid esters, fatty acid amides, glycerides, phospholipids, ...),, esters of sucrose, water, triethyl citrate, polyethylene glycol,, dibutyl sebate, butyl stearate, glycerol monostearate, diethyl phthalate, their derivatives and their mixtures .
For example, according to the invention, the phospholipids can be lecithins such as soya lecithin, sunflower lecithin or egg yolk lecithin.
According to the invention, the preferred plasticizers are glycerol, water, polyethylene glycol and triethyl citrate.
Preferably, the composition according to the invention further comprises at least one additive chosen from the group consisting of lubricating agents, surfactants, antioxidants, chelating agents, their derivatives and their mixtures.
By way of example, the following compounds can be used, alone or as a mixture, as lubricating agents in a composition according to the invention: glycerol dibhenate, talc, silica, stearic acid, boric acid, waxes, sodium oleate, sodium acetate, magnesium stearate, calcium stearate, sodium stearate, sodium benzoate, sodium lauryl sulfate, glycerol distearate, palmitostearate of glycerol, microcrystalline cellulose or even polyoxyl-8-glycerides.
By way of example, the following compounds can be used, alone or as a mixture, as surfactant agents in a composition according to the invention: Pluronic®, Span®, Cremophor®, polysorbates (Tween®, etc.) , vitamin E TPGS and sodium ducosate.
By way of example, the following compounds can be used, alone or as a mixture, as antioxidant and / or chelating agents in a composition according to the invention: butylated hydroxytoluene, butylated hydroxyanisiole, EDTA, citric acid and vitamin E.
Advantageously, the composition according to the invention further comprises at least one additional compound of polyphenol type chosen from the group consisting of phenolic acids, stilbenes, phenolic alcohols, lignans, flavonoids, their derivatives and their mixtures. In particular, the glycosylated and aglycone forms of the polyphenols are envisaged as an additional active principle according to the present invention. More particularly, within the meaning of the present invention, the term “polyphenol” denotes both polyphenols of natural origin and synthetic polyphenols but also all polyphenol derivatives.
By way of example, within the meaning of the present invention, there may be mentioned as phenolic acids, derivatives of hydroxybenzoic acid (gallic acid, tannic acid, etc.) and derivatives of hydroxycinamic acid (curcumin, coumaric acid. , caffeic acid, ferulic acid,…).
By way of example, within the meaning of the present invention, there may be mentioned as stilbenes, resveratrol, sirtinol, piceatannol or else polydatin.
By way of example, within the meaning of the present invention, there may be mentioned as flavonoids, flavanoles (quercetin, myricetin, kaempferol, isornamnetin, morine, rutin, tiliroside, trinydroxyethylrutin, fisetin, etc.), flavones (apigenin, luteolin, baicalein, chrysin, diosmin, nobiletin, tangeretin, wogonin, aminogenistein,…), flavanones (bavachin, 8-isopentenylnaringenin, isoxanthohumole, naringenin, eriodictyole, hesperetin, silylavin, isilylavin,… daidzin, formonetin, genistin, neobavaoflavone, pueranin,…), antocianidins (cianidin, pelargonidin, delphinidin, petunidin, malvidin,…) and flavanols (cathechins, gallocatechin, epigallocatechingallate,…).
According to the invention, said at least one additional active principle of polyphenol type constitutes an inhibitor / modulator of efflux pumps including P-gp.
Preferably, the composition according to the invention further comprises at least one inhibitor and / or a modulator of the activity of P-gp.
Preferably, the composition according to the invention is packaged in the form of pellets, flakes, granules, powders, effervescent or non-effervescent tablets, injectable or non-injectable solutions, suspensions, gels, ointments or even in any other form suitable for administration to an animal or human.
Other embodiments of a composition according to the invention are indicated in the appended claims.
A subject of the invention is also a manufacturing process, in particular a manufacturing process by thermoforming, of a composition in the form of a thermoformed extrudate according to the invention, characterized in that it comprises the following steps:
a) a step of simultaneous or delayed supply of at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, to feed an extruder,
b) a step of mixing, in said extruder, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms and said at least one polymer chosen from the group consisting of natural proteins or synthetic, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, to form a mixture, and c) a step of hot extrusion of said mixture obtained in step b) in said extruder to obtain a thermoformed extrudate in which said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprises / comprise at least a first amorphous phase and optionally a second crystalline phase.
Such a process according to the invention gives rise to a composition in the form of a thermoformed extrudate, that is to say obtained by thermoforming and more particularly by hot extrusion, in which said at least one triterpene and / or said au at least one triterpenoid and / or said at least one of their glycosylated forms as active principle (s) comprises (comprise) at least a first amorphous phase and optionally a second crystalline phase dispersed within said at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures.
This composition according to the invention has a significantly higher solubility (s) and / or dispersion (s) in aqueous phase (aqueous medium) of said at least one triterpene and / or of said at least one. triterpenoid and / or said at least one of their glycosylated forms and simultaneously a significantly increased bioavailability (s) of said at least one triterpene and / or of said at least one triterpenoid and / or of said at least one of their glycosylated forms relative to the solubilities and bioavailability of these compounds for current compositions.
It has been shown that the composition according to the invention is in the form of a thermoformed extrudate in which said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms (principle (s ) active agent (s)) comprising at least a first amorphous phase and optionally a second crystalline phase is (are) dispersed within said at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides , natural or synthetic polysaccharides, their derivatives and their mixtures.
It has also been shown, in the context of the present invention, that said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms is (are) not degraded (s). ) even during the manufacturing process, in particular during the manufacturing process by thermoforming, of the composition in the form of a thermoformed extrudate which nevertheless involves the submission of said at least one triterpene and / or of said at least one triterpenoid and / or of said at least one of their high temperature glycosylated (HME) forms. Moreover, it has also been put forward that said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms in a composition in the form of a thermoformed extrudate according to the invention is therein. (are) evenly distributed.
More particularly, the hot extrusion (Hot Melt Extrusion - HME) carried out according to the manufacturing process by thermoforming according to the invention gives rise to a melting of the active principle (s) (said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms) and / or said at least one polymer at a temperature greater than or equal to their melting point.
However, according to certain embodiments of a composition according to the invention, this melting of the active principle (s) and / or of the polymer can take place at a temperature below their melting point. This is the case, for example, if the composition according to the invention comprises a plasticizing agent or if the active principle (s) itself (themselves) exhibit (exhibit) plasticizing properties. Such a melting of the active principle (s) and / or of the polymer gives rise to a solid dispersion in which the active principle (s) (said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms) comprising at least a first amorphous phase and optionally a second crystalline phase is (are) dispersed (s) / distributed (s) / distributed (s) homogeneously within said at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures.
Advantageously, the process according to the invention comprises a preliminary step of premixing said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms and said at least one polymer chosen from the group. group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, so as to form a premix intended to feed the extruder.
Preferably, according to the process according to the invention, said hot extrusion step is carried out at an extrusion temperature or thermoforming temperature of between 20 and 300 ° C, preferably at a temperature of between 40 and 270 ° C, preferably at a temperature between 50 and 250 ° C, preferably at a temperature between 60 and 230 ° C, more preferably at a temperature between 70 and 220 ° C, more preferably at a temperature between 80 and 200 ° C, more preferably at a temperature between 90 and 180 ° C, more preferably at a temperature between 100 and 170 ° C, more preferably at a temperature between 120 and 160 ° C, more preferably at a temperature between 125 and 150 ° C.
Advantageously, according to the process according to the invention, said hot extrusion step is carried out at a speed of rotation of an extrusion screw of between 20 and 900 revolutions / min, preferably between 50 and 300 revolutions / min , preferably between 100 and 250 revolutions / min, preferably equal to 250 revolutions / min, preferably equal to 100 revolutions / min.
Preferably, the method according to the invention comprises an additional step of cooling at the outlet of the extruder.
Advantageously, the method according to the invention comprises an additional step of processing the thermoformed extrudate at the outlet of the extruder, for example cutting at a pelletizer and / or grinding said thermoformed extrudate.
Other embodiments of the process according to the invention are indicated in the appended claims.
The present invention also relates to a composition in the form of a thermoformed extrudate obtained according to the process according to the invention, said composition comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms as principle. active agent and at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and mixtures thereof, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase.
In other words, the present invention also relates to a composition in the form of a thermoformed extrudate obtained by thermoforming, in particular by hot extrusion (HME - Hot Melt Extrusion), said composition comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms as active principle and at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase.
The present invention also relates to a use of a composition according to the invention as a food supplement and / or as a cosmetic product and / or as a medicament for human or veterinary use.
A composition according to the invention preferably exhibits anti-inflammatory, lipid-lowering, antioxidant, antithrombotic, anti-tumor and anti-diabetic properties as well as neuroprotective properties.
In particular, the present invention relates to a composition for use in the preventive and / or curative treatment, in humans and / or in animals, of pathologies linked to inflammation (osteoarthritis, tendonitis, injuries, etc. .), pathologies related to premature aging of cells, pathologies related to the cardiovascular system (hypotension, hypertension, vasoconstriction, ventricular hypertrophy, arrhythmia, hepatic steatosis, etc.), pathologies related to the blood system (cholesterolemia , platelet aggregation, ...), pathologies related to the gastrointestinal system (diarrhea, digestive inflammation, modulation of the intestinal microbiota, ...), pathologies related to the endocrine system (hyperglycemia, ...), pathologies related to the immune system, pathologies related to the central nervous system, skin diseases, diseases due to the presence of microorganisms and cancers (anti-tumor, …) And in the preventive and / or curative treatment of diabetes.
More particularly, the present invention relates to a composition for use in the preventive and / or curative treatment, in humans and / or in animals, diseases related to the joints, muscles and tendons, diseases related to premature aging of cells, obesity, diabetes, high cholesterol, metabolic syndrome and irritable bowel syndrome (IBS).
Other forms of use of a composition according to the invention are indicated in the appended claims.
Other characteristics, details and advantages of the invention will emerge from the examples given below, without limitation and with reference to the appended figures.
FIG. 1 is a graph illustrating the rate of solubilization of boswellic acids over time for various examples of compositions, in particular for various examples of thermoformed compositions, according to the invention.
Figures 2 and 3 are graphs illustrating the rates of dispersion over time of examples of different compositions, in particular for examples of different thermoformed compositions, according to the invention.
FIG. 4 is a graph illustrating the rate of solubilization of bacosides over time for various examples of compositions, in particular for various examples of thermoformed compositions, according to the invention.
FIG. 5 is a graph illustrating the rate of solubilization of asiaticoside over time for various examples of compositions, in particular for various examples of thermoformed compositions, according to the invention.
FIG. 6 is a graph illustrating the degree of dispersion of ursolic acid over time for various examples of compositions, in particular for various examples of thermoformed compositions, according to the invention. Examples Example 1: Process for the manufacture by thermoforming of a composition according to the invention in the form of a thermoformed extrudate Thermoformed compositions according to the invention comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms comprising at least one amorphous phase, such as those forming the subject of Example 2 below, were obtained according to the following process also forming the subject of the present invention: a) a pre- mixture of at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms in the crystalline state in powder form and at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures; b) a step of supplying said premix formed in step a) to feed a Pharma 11 type extruder from Thermo-Fischer®; c) a step of mixing, in said extruder, said premix to obtain a mixture; d) a thermoforming step by hot extrusion of said mixture obtained in step c) in said extruder to obtain an extrudate, thermoformed, the hot extrusion step being carried out at a speed of rotation of a screw of extrusion at 100 revolutions / minute and at a temperature between 40 ° C and 180 ° C; e) a step of cooling at the outlet of the extruder of said thermoformed extrudate obtained in step d); and f) a cutting / grinding step, at the level of a mill, of the cooled thermoformed extrudate obtained in step e) so as to obtain a homogeneous powder.
The hot extrusion temperature (thermoforming temperature) at which the hot extrusion step is carried out is determined by the type of constituents used, in particular according to the type of polymer and / or plasticizer used. implementation, which the skilled person is able to determine.
Moreover, a person skilled in the art, in particular depending on the type of extruder employed and in accordance with the general principle of hot extrusion (HME), is able to define possible temperature levels in different zones along the or extrusion screws such that a gradual increase in temperature takes place within the material transported by the extrusion screw (s), this in a direction of advance of the material within the extruder.
Typically, between zones defined along the extrusion screw (s), temperature differences of the order of 0 to 40 ° C are observed.
For example, in the context of the present invention, the compositions tested below were obtained in a Pharma 11 type extruder from Thermo-Fischer® having 9 temperature zones which are as follows in a direction of advance of the material moving at a speed of 100 revolutions / minute: zone 1 (extruder feed zone) = ambient temperature; zone 2 = 120 ° C; zone 3 = 120 ° C; zone 4 = 120 ° C; zone 5 = 130 ° C; zone 6 = 140 ° C; zone 7 = 150 ° C; zone 8 = 155 ° C; zone 9 (sector) = 160 ° C.
Example 2: Solubility test of thermoformed compositions according to the invention comprising an extract of Boswellia serrata standardized to 65% of boswellic acids Different thermoformed compositions, obtained according to the manufacturing process described in Example 1, were tested in terms of solubility of boswellic acids present in an extract of Boswellia serrata standardized to 65% boswellic acids.
This solubility was measured over time from the thermoformed extrudates obtained according to the invention.
As indicated above, the thermoformed extrudates are in the form of a homogeneous powder (ground material) in which the triterpene and / or the triterpenoid comprises at least one amorphous phase.
The solubility tests were all carried out with a vane dissolution apparatus starting with approximately 2 g of thermoformed extrudate, at a temperature of 37 ° C with stirring at 50 revolutions / minute in 450 ml of a dissolution medium. 0.1N HCl.
These solubility tests were carried out according to the recommendations of the pharmacopoeia Ph.Eur.9.0 (Recommendations on - Dissolution Testing). At determined times (after 30 min and after 2 h), a sample of 1 ml of the mixture was taken to carry out a solubility test.
In order to carry out the solubility tests, the tested sample was filtered through a filter (PET, pore size 0.45 μm, Macherey Nagel) before HPLC analysis (Luna column 5 μm C18 (2) 100 A . 100 * 3 mm (Phenomenex); mobile phase: 85% A: methanol and 15% B: water / acetonitrile (95: 5) at pH 2.8; flow rate: 0.6 mL / min; loop: 10 hl, t ° = 40 ° C; wavelengths: 210 nm and 247 nm). In practice, the solubility of triterpenes and / or triterpenoids, in particular the solubility of boswellic acids contained in an extract of Boswellia serrata standardized to 65% boswellic acids, was evaluated by HPLC assay of the 6 main boswellic acids (the a-boswellic acid, B-boswellic acid, 11-keto- B- boswellic acid (KBA), acetyl- 11-keto- B-boswellic acid (AKBA), acetyl a-boswellic acid, acetyl B-boswellic acid) present in this extract of Boswellia serrata.
The thermoformed compositions according to the invention listed in Table 1 were formulated according to the process of the invention and tested in terms of solubility over time according to the principle indicated above (dosage of the 6 main boswellic acids: the results presented are the solubility means calculated by summing the solubilities of each of the 6 boswellic acids and dividing this sum by 6). A single extract of Boswellia serrata standardized to 65% boswellic acids in native crystalline form and in powder form (native BW) was used as a control.
The amounts mentioned in Table 1 are percentages by weight of the compounds used (subjected to the process according to the invention) relative to the total weight of the composition.
Table 1 Glycerol extract (2) Boswellia serrata protein (65%) (1) (1) Dry extract of Boswellia serrata standardized to 65% boswellic acids (Vidya Herbs) (2) Glycerol (Sigma-Aldrich) (3) Fish collagen with a molecular weight of 3000 Da (Green Snow) (4) Hydrolyzed fish collagen with a molecular weight of less than 3000 Da (Kenney & Ross Ltd.) (5) Bovine gelatin with a molecular weight of between 1000 and 3000 Da (Lapi geltine SPA) The results obtained are presented in FIG. 1. As can be seen, the natural proteins of the collagen / gelatin type, used as a polymer, make it possible to increase the solubility of triterpenes and of triterpenoids, in particular. boswellic acids.
Note that the solubility of boswellic acids varies depending on the type / nature of collagen / gelatin but that this solubility is always increased compared to the control.
Example 3: dispersion test of thermoformed compositions according to the invention comprising an extract of Boswellia serrata standardized to 65% of boswellic acids Different thermoformed compositions, obtained according to the manufacturing process described in Example 1, were tested in terms of dispersion of boswellic acids present in an extract of Boswellia serrata standardized to 65% boswellic acids. The dispersion was measured over time from the thermoformed extrudates obtained according to the invention. As indicated above, the thermoformed extrudates are in the form of a homogeneous powder (ground material) in which the triterpene and / or the triterpenoid comprises at least one amorphous phase.
The dispersion tests were all carried out with a vane dissolution apparatus starting with approximately 2 g of thermoformed extrudate, at a temperature of 37 ° C with stirring at 50 revolutions / minute in 450 ml of a dissolution medium. 0.1N HCl.
In order to carry out the dispersion tests, samples taken at determined times (after 30 min and after 2 h) were diluted in an appropriate solvent (mobile phase for PHPLC) then filtered through a filter (PET, pore size 0.45 μm, Macherey Nagel) before HPLC analysis (Luna column 5 μm C18 (2) 100 A. 100 * 3 mm (Phenomenex); mobile phase: 85% A: methanol and 15% B: water / acetonitrile (95 : 5) at pH 2.8; flow rate: 0.6 mL / min; loop: 10 hl, t ° = 40 ° C; wavelengths: 210 nm and 247 nm).
In practice, the dispersion of the triterpenes and / or of the triterpenoids, in particular the dispersion of the boswellic acids contained in an extract of Boswellia serrata standardized to 65% of boswellic acids, was evaluated by HPLC assay of the 6 main boswellic acids (the a-boswellic acid, B-boswellic acid, 11-keto- B- boswellic acid (KBA), acetyl- 11-keto- B-boswellic acid (AKBA), acetyl a-boswellic acid, acetyl B-boswellic acid) present in this extract of Boswellia serrata.
The thermoformed compositions according to the invention listed in Table 2 were formulated according to the process of the invention and tested in terms of aqueous dispersion over time according to the principle indicated above (dosage of the 6 main boswellic acids: the results presented are the dispersion averages calculated by summing the dispersions of each of the 6 boswellic acids and dividing this sum by 6). A single extract of Boswellia serrata standardized to 65% boswellic acids in native crystalline form and in powder form (native BW) was used as a control.
The amounts mentioned in Table 2 are percentages by weight of the compounds used (subjected to the process according to the invention) relative to the total weight of the composition.
Table 2 Extractfrom | Glycerol (2) Protein | Polysaccharide Boswellia serrata (65%) (1) in | B | ® | © | sw wr | 8 | 8 | ww | . ms | 8 | 6 | BB | 9 (1) Dry extract of Boswellia serrata standardized to 65% boswellic acids (Vidya Herbs) (2) Glycerol (Sigma-Aldrich) (3) Cleargum CB90 modified starch (Arugula) (4) Rice protein (Green Snow) (5) Pumpkin seed protein (Green Snow) (6) Hydrolized collagen-5000 Da (Rousselot)
The results obtained are presented in FIG. 2 for compositions 1 to 3 and in FIG. 3 for compositions 4 and 5. As can be seen, each of the thermoformed compositions according to the invention gives rise to a significantly higher percentage of dispersion. to that observed for the extract alone of Boswellia serrata standardized to 65% boswellic acids in native crystalline form and in powder form (native BW).
Example 4 Solubility test of thermoformed compositions according to the invention comprising an extract of Bacopa monierii standardized to 20% bacosides Different thermoformed compositions, obtained according to the manufacturing process described in Example 1, were tested in terms of solubility of the bacosides present in an extract of Bacopa monierii standardized to 20% bacosides. This solubility was measured over time from the thermoformed extrudates obtained according to the invention.
As indicated above, the thermoformed extrudates are in the form of a homogeneous powder (ground material) in which the triterpene and / or the triterpenoid comprises at least one amorphous phase.
The solubility tests were all carried out with a vane dissolution apparatus starting with approximately 4 g of thermoformed extrudate, at a temperature of 37 ° C with stirring at 50 revolutions / minute in 900 ml of a dissolution medium. 0.1N HCl. These solubility tests were carried out according to the recommendations of the pharmacopoeia Ph.Eur.9.0 (Recommendations on Dissolution Testing). At determined times (after 30 min and after 2 h), a sample of 1 ml of the mixture was taken to perform a solubility test.
In order to carry out the solubility tests, the tested sample was centrifuged (10,000 revolutions / minute for 10 min at room temperature, Microstar 17 (VWR)), the supernatant was filtered through a filter (PET, size of pore size 0.45 μm, Macherey Nagel) before HPLC analysis (C18 column, μm 250 * 4.6 mm (Agilent); mobile phase: A: 0.1 mM phosphate buffer and B: Acetonitrile according to the following gradient: Er [AB Dee Flow rate: 1.5 ml / min; loop, 2041; t °: 25 ° C; wavelength 205 nm).
In practice, the solubility of the triterpenes and / or of the triterpenoids, in particular the solubility of the bacosides contained in an extract of Bacopa monierii standardized to 20% of bacosides, was evaluated by HPLC assay of the main 5 bacosides (Bacopaside |, Bacoside A3, Bacopaside II, Jujubogenin, Bacopasaponin C) present in this extract of Bacopa monierii.
The thermoformed compositions according to the invention listed in Table 3 were formulated according to the process of the invention and tested in terms of solubility over time according to the principle indicated above (dosage of the 5 main bacosides: the results presented are the solubility means calculated by summing the solubilities of each of the 5 bacosides and dividing this sum by 5). A single extract of Bacopa monierii standardized to 20% bacosides in native crystalline form and in powder form (native BC) was used as a control. The amounts mentioned in Table 3 are percentages by weight of the compounds used (subjected to the process according to the invention) relative to the total weight of the composition.
Table 3 Bacopa Polysaccharide Glycerol extract (2) | Protein (3) monierii (4) Ka | 8 | # | 8 | #. Ka | 5 | # | 9] 8 (1) Dry extract of Bacopa Monierii standardized to 20% bacosides (Vidya Herbs) (2) Glycerol (Sigma-Aldrich) (3) Hydrolyzed collagen with a molecular weight of 5000 Da (Rousselot) (4) Tackidex C760 (Roquette) The results obtained are presented in FIG. 4. As can be seen, the compositions according to the invention all make it possible to increase the% of solubilized bacosides relative to the control.
Example 5: Solubility test of thermoformed compositions according to the invention comprising asiaticoside Different thermoformed compositions, obtained according to the manufacturing process described in Example 1, were tested in terms of solubility of asiaticoside.
This solubility was measured over time from the thermoformed extrudates obtained according to the invention.
As indicated above, the thermoformed extrudates are in the form of a homogeneous powder (ground material) in which the triterpene and / or the triterpenoid comprises at least one amorphous phase.
The solubility tests were all carried out with a vane dissolution apparatus starting with approximately 2 g of thermoformed extrudate, at a temperature of 37 ° C with stirring at 50 revolutions / minute in 900 ml of a dissolution medium. 0.1N HCl. These solubility tests were carried out according to the recommendations of the pharmacopoeia Ph.Eur.9.0 (Recommendations on Dissolution Testing). At determined times (after 30 min and after 2 h), a sample of 1 ml of the mixture was taken to perform a solubility test.
In order to carry out the solubility tests, the tested sample was centrifuged (10,000 revolutions / minute for 10 min at room temperature, Microstar 17 (VWR)), the supernatant was filtered through a filter (PET, size of pores of 0.45 μm, Macherey Nagel) before HPLC analysis (C18 column, 5um 250 * 4.6 mm (Agilent); mobile phase: A: Water and B: Acetonitrile according to the following gradient: Test AB CE ER a Flow rate: 1 ml / min; loop, 101; t °: 25 ° C; wavelength 205 nm).
In practice, the solubility of triterpenes and / or triterpenoids, in particular the solubility of asiaticoside, was evaluated by HPLC assay.
The thermoformed compositions according to the invention listed in Table 4 were formulated according to the process of the invention and tested in terms of solubility over time according to the principle indicated above. Asiaticoside in native crystalline form and in powder form (native AS) was used as a control. The amounts mentioned in Table 4 are percentages by weight of the compounds used (subjected to the process according to the invention) relative to the total weight of the composition.
Table 4 Asiaticoside Polysaccharide Glycerol (2) | Protein (3) LT mare PE oz | wW | # | 9 | F (1) Asiaticoside (FyzCo) (2) Glycerol (Sigma-Aldrich) (3) Hydrolyzed collagen with a molecular weight of 5000 Da (Rousselot) (4) Tackidex C760 (Roquette) The results obtained are presented in FIG. 5. As can be seen, the compositions according to the invention all make it possible to increase the% of solubilized asiaticoside relative to the control.
Example 6: dispersion test of thermoformed compositions according to the invention comprising ursolic acid Different thermoformed compositions, obtained according to the manufacturing process described in Example 1, were tested in terms of dispersion of ursolic acid. The dispersion was measured over time from the thermoformed extrudates obtained according to the invention. As indicated above, the thermoformed extrudates are in the form of a homogeneous powder (ground material) in which the triterpene and / or the triterpenoid comprises at least one amorphous phase.
The dispersion tests were all carried out with a vane dissolution apparatus starting with approximately 2 g of thermoformed extrudate, at a temperature of 37 ° C with stirring at 50 revolutions / minute in 900 ml of an HCl dissolution medium. 0.1N.
In order to carry out the dispersion tests, samples taken at determined times (after 30 min and after 2 h) were diluted in an appropriate solvent (mobile phase for PHPLC) then filtered through a filter (PET, pore size 0.45 μm, Macherey Nagel) before HPLC analysis (Luna column 5 μm C18 (2) 100 A. 100 * 3 mm (Phenomenex); mobile phase Acetonitrile / Water / 0.5% Ammonium acetate (67: 12 : 21) flow rate: 1 mL / min; loop: 10 ul, t ° = 25 ° C; wavelengths: 210 nm).
In practice, the dispersion of triterpenes and / or triterpenoids, in particular the dispersion of ursolic acid, was evaluated by HPLC assay.
The thermoformed compositions according to the invention listed in Table 5 were formulated according to the process of the invention and tested in terms of aqueous dispersion over time according to the principle indicated above. Ursolic acid in native crystalline form and in powder form (native AU) was used as a control. The amounts mentioned in Table 5 are percentages by weight of the compounds used (subjected to the process according to the invention) relative to the total weight of the composition.
Table 5 Acid Polysaccharide Glycerol (2) | Protein (3) ee Ee wt | 6 | B | # | © _ en | w | # | 8 | w # we: | © | # | ® | w® (1) Ursolic acid (Fyzco) (2) Glycerol (Sigma-Aldrich) (3) Hydrolyzed collagen with a molecular weight of 5000 Da - (Rousselot) (4) Tackidex C760 (Roquette) The results obtained are presented in FIG. 6. As can be seen, the compositions according to the invention all make it possible to increase the% of ursolic acid dispersed relative to the control.
The present invention has been described in relation to specific embodiments, which have a purely illustrative value and should not be considered as limiting.
In general, it will be obvious to those skilled in the art that the present invention is not limited to the examples illustrated and / or described above.
The use of the verbs "to understand", = "to include", "to include", or any other variant, as well as their conjugations, can in no way exclude the presence of elements other than those mentioned.
The use of the indefinite article "a", "a", or of the definite article "the", "the" or "the", to introduce an element does not exclude the presence of a plurality of these elements.

权利要求:
Claims (23)
[1]
1. Composition in the form of a thermoformed extrudate comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least one polymer chosen from the group consisting of natural or synthetic proteins, oligosaccharides natural or synthetic, natural or synthetic polysaccharides, their derivatives and their mixtures, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase, said composition comprising at least one plasticizer.
[2]
2. Composition according to claim 1, characterized in that said thermoformed extrudate comprises a thermoformed mixture of said at least one triterpene and / or of said at least one triterpenoid and / or of said at least one of their glycosylated forms and of said at least one polymer. chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures.
[3]
3. Composition according to claim 1 or 2, characterized in that said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms predominantly comprises at least one first amorphous phase.
[4]
4. Composition according to claim 3, characterized in that said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprises between 51 and 100% by mass of an amorphous phase and between 0 and 49% by mass of a crystalline phase.
[5]
5. Composition according to any one of the preceding claims, characterized in that said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms is tetracyclic, such as for example oleandrine, euphol or cucurbitacin, or pentacyclic, such as for example betulinic acid, oleanolic acid, a boswellic acid, ursolic acid, lupeol, asiatic acid, madecassic acid, maslinic acid, jujubogenin or pseudojujubogenin.
[6]
6. Composition according to claim 5, characterized in that said boswellic acid is selected from the group consisting of a- and B-boswellic acids, for example a-boswellic acid, acetyl-a-boswellic acid, B-boswellic acid, acetyl-B-boswellic acid, 9,11-dehydro-a-boswellic acid, acetyl-9,11-dehydro-a-boswellic acid, 9,11-dehydro acid -B-boswellic, acetyl-9,11-dehydro-B- boswellic acid, 11-keto-B-boswellic, 11-keto-a-boswellic acid, 3-acetyl-11-keto a-boswellic and 3-acetyl-11-keto-B-boswellic acid.
[7]
7. Composition according to any one of the preceding claims, characterized in that said natural or synthetic proteins are chosen from the group consisting of glycoproteins, collagens and / or collagen hydrolysates, plant proteins, animal proteins, their. derivatives and their mixtures.
[8]
8. Composition according to claim 7, characterized in that said collagens and / or said collagen hydrolysates have a molecular weight of between 50 and 300,000 Da, preferably between 100 and 275,000 Da, preferably between 150 and 250,000 Da, preferably. between 200 and 225,000 Da, preferably between 250 and 200,000 Da, preferably between 300 and 175,000 Da, preferably between 350 and 150,000 Da, preferably between 400 and 125,000 Da, preferably between 450 and 100,000 Da, preferably between 500 and 75,000 Da, preferably between 550 and 50,000 Da, preferably between 600 and 40,000 Da, preferably between 650 and 30,000 Da, preferably between 700 and 20,000 Da, preferably between 750 and 10,000 Da, preferably between 800 and 9,000 Da, preferably between 850 and 8000 Da, preferably between 900 and 7000 Da,
preferably between 950 and 6000 Da, preferably between 1000 and 5000 Da, preferably between 1050 and 4000 Da, preferably between 1100 and 3000 Da, preferably between 1150 and 2000 Da, preferably between 1200 and 1000 Da.
[9]
9. Composition according to any one of the preceding claims, characterized in that said oligosaccharides are chosen from the group consisting of cyclodextrin, raffinose, rnamminose, rhamnose, stachyose, verbascose, trehalose, lactose, lactulose, maltose, their derivatives and their mixtures.
[10]
10. Composition according to any one of the preceding claims, characterized in that said natural or synthetic polysaccharides are chosen from the group consisting of starches, fibers, celluloses, hemicelluloses, glycogen, B-glucan, linulin, amylopectin, amylose, dextrin, maltodextrin, isomaltose, xylan, pullulan, agar-agar, carrageenans, mannans, fucoidan, gums, chitosan , chitin, xanthan, levan, neoserin, hyaluronic acid, hyaluronates, chondroitin sulphate, dermatan sulphate, keratan sulphate, their derivatives and their mixtures.
[11]
11. Composition according to any one of the preceding claims, characterized in that it further comprises at least one additional natural or synthetic polymer chosen from the group consisting of polyvinyl acetate, polyvinylpyrrolidone (PVP), acetate. polyvinylpyrrolidone-co-vinyl, polyethylene-co-vinyl acetate, co-methacrylic acid polyvinyl acetate, polyethylene oxide, polylactide-co-glycolide, polyvinyl alcohol, polycarbophil, polycaprolactone, carnauba wax, ethylene-vinyl copolymer, lecithin, castor oil, hydrogenated soybean oil, waxes, isomalt, their derivatives and their mixtures.
[12]
12. Composition according to any one of the preceding claims, characterized in that said at least one plasticizer is chosen from the group consisting of polyols, lipids, sucrose esters, water, triethyl citrate, polyethylene glycol, dibutyl sebate, butyl stearate, glycerol monostearate, diethyl phthalate, their derivatives and mixtures thereof.
[13]
13. Composition according to any one of the preceding claims, characterized in that it further comprises at least one additive chosen from the group consisting of lubricating agents, surfactants, antioxidants, chelating agents, their derivatives and of their mixtures.
[14]
14. Composition according to any one of the preceding claims, characterized in that it further comprises at least one first additional compound of polyphenol type chosen from the group consisting of phenolic acids, stilbenes, phenolic alcohols, lignans, flavonoids, their derivatives and their mixtures.
[15]
15. Composition according to any one of the preceding claims, characterized in that it is packaged in the form of pellets, flakes, granules, powders, effervescent tablets or not, injectable or non-injectable solutions, suspensions, gels, ointments or even in any other suitable form allowing administration to an animal or a human being.
[16]
16. Manufacturing process, in particular manufacturing process by thermoforming, of a composition in the form of a thermoformed extrudate according to any one of claims 1 to 15, characterized in that it comprises the following steps: a) a simultaneous or delayed supply step over time of at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms and at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, to feed an extruder, b) a step of mixing, in said extruder, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms and said at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, to form a mixture, and c) a step of hot extrusion of said mixture obtained in step b) in said extruder to obtain a thermoformed extrudate in which said at least a triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprises / comprise at least a first amorphous phase and optionally a second crystalline phase.
[17]
17. The method of claim 16, characterized in that it comprises a prior step of premixing said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms and said at least one triterpene. least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, so as to form a premix intended to feed the extruder.
[18]
18. The method of claim 16 or 17, characterized in that said hot extrusion step is carried out at an extrusion temperature between 20 and 300 ° C, preferably at a temperature between 40 and 270 ° C, preferably at a temperature between 50 and 250 ° C, preferably at a temperature between 60 and 230 ° C, more preferably at a temperature between 70 and 220 ° C, more preferably at a temperature between 80 and 200 ° C , more preferably at a temperature between 90 and 180 ° C, more preferably at a temperature between 100 and 170 ° C, more preferably at a temperature between 120 and 160 ° C, more preferably at a temperature between 125 and 150 ° C.
[19]
19. Method according to any one of claims 16 to 18, characterized in that said hot extrusion step is carried out at a speed of rotation of an extrusion screw of between 20 and 900 revolutions / min, preferably. between 50 and 300 revolutions / min, preferably between 100 and 250 revolutions / min, preferably equal to 250 revolutions / min, preferably equal to 100 revolutions / min.
[20]
20. A method according to any one of claims 16 to 19, characterized in that it comprises an additional step of cooling at the outlet of the extruder.
[21]
21. A method according to any one of claims 16 to 20, characterized in that it comprises an additional step of treating the thermoformed extrudate at the outlet of the extruder, for example a cut at a pelletizer and / or grinding said thermoformed extrudate.
[22]
22. Composition in the form of a thermoformed extrudate according to any one of claims 1 to 15 for use in the preventive and / or curative treatment, in humans and / or in animals, of pathologies linked to inflammation, pathologies related to premature aging of cells, pathologies related to the cardiovascular system, pathologies related to the blood system, pathologies related to the gastrointestinal system, pathologies related to the endocrine system, pathologies linked to the immune system, pathologies linked to the central nervous system, skin diseases, diseases due to the presence of microorganisms and cancers and in the preventive and / or curative treatment of diabetes.
[23]
23. Composition in the form of a thermoformed extrudate obtained according to the process according to any one of claims 16 to 21, said composition comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms such as active principle and at least one polymer chosen from the group consisting of natural or synthetic proteins, natural or synthetic oligosaccharides, natural or synthetic polysaccharides, their derivatives and their mixtures, said at least one triterpene and / or said at least one triterpenoid and / or said at least one of their glycosylated forms comprising at least a first amorphous phase and optionally a second crystalline phase.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BE1025649B1|2019-05-20|Composition comprising at least one protoberberine alkaloid and its method of manufacture

---

TW200836771A|2008-09-16|Particulate composition comprising bioactive substance and method of producing the same

---

US20120301546A1|2012-11-29|Acid-resistant soft gel compositions

---

KR102263277B1|2021-06-10|formulation comprising particles

---

Li et al.2018|Controlled release system by active gelatin film incorporated with β-cyclodextrin-thymol inclusion complexes

---

Akolade et al.2017|Encapsulation in chitosan-based polyelectrolyte complexes enhances antidiabetic activity of curcumin

---

WO2019008101A1|2019-01-10|Enteric coated solid dosage form comprising omega-3 fatty acid amino acid salts

---

US20180263953A1|2018-09-20|Sustained Release Cannabinoid Formulations

---

IL275430D0|2020-08-31|Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof

---

EP2931289B1|2019-04-17|Chitin or derivatives thereof for the prevention and/or treatment of parasitoses

---

Wang et al.2013|Characterizations and microsphere formulation of polysaccharide from the marine clam |

---

Abdellatif et al.2018|A novel controlled release microsponges containing Albendazole against Haemonchus contortus in experimentally infected goats

---

AU2014380905A1|2016-09-08|Composition of oily, pungent and odoriferous substances and a process of preparation thereof

---

BE1027350B1|2021-06-22|Composition comprising at least one triterpene and / or at least one triterpenoid and / or at least one of their glycosylated forms

---

Hu et al.2020|The preparation, characterization, anti-ultraviolet and antimicrobial activity of gelatin film incorporated with berberine-HP-β-CD

---

FR2898817A1|2007-09-28|ASSOCIATION OF OLEAGINOUS SUBSTANCE WITH A MIXTURE OF AT LEAST TWO CYCLODEXTRINS

---

BE1027067B1|2020-09-11|Composition comprising curcumin

---

Jain et al.2010|Alternative extrusion–spheronization aids

---

BE1028182A1|2021-10-27|Composition comprising at least one protobberberine alkaloid and its manufacturing process

---

EP3188713B1|2020-02-12|Method of inducing satiety

---

FR3097737A3|2021-01-01|Composition comprising curcumin

---

WO2019208668A1|2019-10-31|Soft capsule film composition

---

JP6942342B2|2021-09-29|Soft capsule film

---

JP5044767B2|2012-10-10|Pigmentation inhibitor and use thereof

---

JP2005170863A|2005-06-30|Soft elastic capsule using starch composition, method for producing the same and automatic machine for producing the same

同族专利:

---

公开号 | 公开日

---

WO2020260413A1|2020-12-30|

---

BE1027350A1|2021-01-13|

---

CA3142991A1|2020-12-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US5260074A|1992-06-22|1993-11-09|Digestive Care Inc.|Compositions of digestive enzymes and salts of bile acids and process for preparation thereof|

---

EP0599282A1|1992-11-27|1994-06-01|BIOPROGRESS S.p.A.|Pharmaceutical compositions containing ursodeoxycholic acid|

---

EP1391426A1|2002-08-12|2004-02-25|Bio Minerals N.V.|Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate|

---

US20180085316A1|2015-05-06|2018-03-29|Insucaps Limited|Gelated microparticle suitable for oral delivery of therapeutic peptides to the lower intestine|

---

US20180263270A1|2015-10-07|2018-09-20|Dsm Ip Assets B.V.|Multivitamin extrudates|

---

WO2019038430A1|2017-08-25|2019-02-28|Eleonor Sprl|Composition comprising at least one protoberberine alkaloid and its production process|

---

法律状态:
2021-07-19| FG| Patent granted|Effective date: 20210622 |

优先权:

---

申请号 | 申请日 | 专利标题

---

BE201905419|2019-06-28|

---

BE201905448|2019-07-10|

---

BE202005254|2020-04-17|

---